Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06860945

Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain

Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy.

Methods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical/vaginal swab, ulcer) is performed. Primary outcome variable: development of an STI (Yes/No). The following STIs will be considered: syphilis, Neisseria gonorrhoeae (NG) infection, Chlamydia trachomatis (CT) infection, lymphogranuloma venereum (LGV), Mycoplasma genitalium (MG) infection, genital herpes, hepatitis A, hepatitis B, hepatitis C, HIV infection, and MPOX. Secondary outcome variable: number of diagnosed STIs. In order to determine factors associated with acquiring an STI, multivariate analyses will be conducted using logistic regression. The best models will be analyzed in the validation population. To compare the models, we will follow the Bayesian approach suggested by Benavoli et al.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitario de Torrecárdenas, Almería, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All individuals with documented initiation of oral PrEP (daily or event-driven regimens), who have collected the medication at least once and have taken at least one pill, will be included in the study.

The approved criteria for the use of oral PrEP in Spain, as recommended by the Spanish Gesida guidelines (GeSIDA. Recomendaciones sobre la Profilaxis Pre-Exposición para la Prevención de la Infección por VIH en España. Marzo 2023. Available at http://.gesida-seimc.org/category/guias-clinicas/otras-guias-vigentes/), are as follows:

  • People without HIV infection at the time of cohort inclusion
  • Age ≥ 16 yr who meet the following criteria:
  • MSM and transgender women with at least two of the following criteria during the last year: > 10 sexual partners; Condomless anal sex; Chemsex; PEP; ≥ 1 STI
  • Sex worker women who report non-habitual use of condoms.
  • Cisgender males/females, who report condomless and present at least two of the same criteria as MSM and transgender.
  • PWID with unsafe injection practices

Exclusion criteria

none

-

Treatment and study plan

No Intervention: Observational Cohort

Other

No Intervention: Observational Cohort

Primary outcomes

  1. STI predictive model

    Time frame: through study completion, an average of 5 years

    Predictive model for the acquisition of sexually transmitted infections in individuals using PrEP within the national provision program for this strategy

Secondary outcomes

  1. STI incidence

    Time frame: through study completion, an average of 5 years

    Incidence of sexually transmitted infections (STIs) in the cohort globally and by type of infection.

  2. STI dynamics

    Time frame: through study completion, an average of 5 years

    Evolution of STI diagnoses during follow-up among PrEP users included in the study, both globally and by specific pathogen

  3. asymptomatic STIs

    Time frame: through study completion, an average of 5 years

    Proportion of asymptomatic STIs diagnosed within the screening program.

  4. behavioral changes

    Time frame: through study completion, an average of 5 years

    Sexual risk behaviors of individuals in the cohort, before and after initiating PrEP

  5. DOXYPEP

    Time frame: through study completion, an average of 5 years

    Proportion of Individuals who might benefit from the 'Doxy-PEP' strategy (doxycycline use as post-exposure prophylaxis for chlamydia and syphilis)

  6. PrEP discontinuation

    Time frame: through study completion, an average of 5 years

    Prevalence of oral PrEP discontinuation within a nationwide PrEP users' cohort.

  7. Predictor of PrEP discontinuation

    Time frame: through study completion, an average of 5 years

    Predictors of oral PrEP discontinuation within a nationwide PrEP users' cohort.

  8. PrEP adherence

    Time frame: through study completion, an average of 5 years

    Self-reported oral PrEP adherence.

  9. Time to discontinuation

    Time frame: through study completion, an average of 5 years

    Time elapsed between oral PrEP initiation and oral PrEP discontinuation.

  10. HIV incident infection

    Time frame: through study completion, an average of 5 years

    Incidence of HIV seroconversions

  11. HIV incident infection

    Time frame: through study completion, an average of 5 years

    Profiles of those who acquire HIV while taking oral PrEP.

Study contacts

Contact information is provided by the study sponsor or research team.

Anaïs Corma-Gómez

CONTACT

[email protected]

+34676170692

Sponsors and collaborators

Lead sponsor

Hospital Universitario de Valme

Other

Collaborators

  • Instituto de Salud Carlos III

Registry information

Acronym: STI_PrEPare

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Mar 6, 2025
Registry last updated
Mar 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.